Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata, a type of hair loss, may be passed through T cells and has genetic links, while treatments vary in effectiveness. Male pattern baldness can be treated with finasteride and is influenced by androgens in hair follicles.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

Alopecia areata often starts around age 23, can be permanent in 30% of cases, and treatments are usually temporary.

Alopecia areata is more common in males, mostly affects the scalp, and often appears as patchy hair loss.

Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.

JAK inhibitors might help treat alopecia areata.

The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.

Corticosteroid therapy reduces specific immune cells and promotes hair growth in alopecia areata patients.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

M-CSF-stimulated myeloid cells can cause alopecia areata in mice.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Alopecia Areata may involve reduced antioxidant defenses in hair follicles, affecting stem cell function.

Steroids may not work well for alopecia areata because of high unoccupied receptors and low thioredoxin levels.

Alopecia areata can regrow hair in a pattern similar to androgenetic alopecia.

A new type of rapid hair loss called ADTA usually gets better on its own within 6 months.

Severe alopecia areata may increase the risk of hidden artery disease.

New treatments for alopecia areata may target specific immune cells and pathways involved in hair loss.

Scalp alopecia areata mostly affects young adult males, often starts suddenly, and usually presents as single, patchy lesions.

The man's hair turned white suddenly but returned to normal on its own in 6 months.

Late-onset alopecia areata in Taiwanese patients is more common in women, usually starts at age 57, often involves less than 10% hair loss, and may have a minimal link to thyroid issues.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.

Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.

Alopecia areata is an autoimmune disease with genetic roots, and treatments include specific topical therapies.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

Diffuse alopecia areata involves more inflammation and higher allergy-related antibodies than patchy types.

Apremilast may help treat hair loss in alopecia areata.

A new mouse model helps understand and find treatments for alopecia areata.